Abstract: The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.

Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Abstract: The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.

Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.

Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.

Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.

Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Abstract: The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.

Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.